Acnetane

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Acnetane

Property Description
Active ingredient Isotretinoin
Form Oral soft gelatin capsule
Pharmacological class Systemic anti-acne agent (Retinoid)
General purpose Management of severe, persistent acne
Origin Synthetic (Vitamin A derivative)

Acnetane: Defining the Systemic Retinoid

The medicine associated with the trade name Acnetane is defined by its core active substance, Isotretinoin, which is classified as a potent systemic anti-acne agent belonging to the class of retinoids. This classification as a systemic agent means that the drug is delivered internally via the oral route of administration, affecting the skin's physiology comprehensively. The compound, chemically designated as 13-cis-retinoic acid, is a synthetic substance chemically derived from Vitamin A. Its primary purpose, clinically utilized for its impact on the disease course, is to address severe and recalcitrant acne conditions that have not responded adequately to standard conventional therapies. Isotretinoin is recognized as a treatment for severe acne.


Composition, Form, and Core Physiological Role

The medicine is supplied as a single-active ingredient product in the form of an oral soft gelatin capsule. The active Isotretinoin is highly lipophilic and is typically suspended in an oil-based vehicle within the capsule to ensure efficient absorption into the system; this particular necessity for fat-based suspension is a key differentiating feature impacting its bioavailability. The unique effectiveness of the substance stems from its powerful regulatory effects on skin biology. The primary physiological role involves causing a substantial reduction in the size and output of the sebaceous glands, thereby significantly inhibiting oil (sebum) production. Additionally, it helps regulate keratinization, preventing the excessive cell growth that clogs pores. This comprehensive mechanism of action makes it a highly potent agent for achieving sustained clearance of lesions, targeting the root causes.

What side effects are possible with Acnetane?

Possible Side Effects and Safety Information

Isotretinoin, the active substance in Acnetane, has a thoroughly documented safety profile that is strictly governed by regulatory authorities due to specific risks.


Safety Constraints and Serious Adverse Reactions

The most critical constraint is its absolute and mandatory contraindication during pregnancy due to the extremely high risk of teratogenicity (severe congenital malformations). This risk necessitates compliance with official risk management programs (e.g., REMS in the US or PPP in Europe). Rare, but officially listed, serious adverse reactions include Inflammatory Bowel Disease (Crohn's disease and ulcerative colitis), Benign Intracranial Hypertension (Pseudotumor cerebri), and severe psychiatric disorders such as depression and suicidal ideation.


Frequency-Classified Adverse Reactions

The majority of documented adverse effects are classified according to frequency in official regulatory documents, primarily affecting the skin, joints, and metabolic systems.

Frequency Category Representative Adverse Reactions
Very Common (ge 1/10) Cheilitis (lip inflammation), dry skin/eyes, back pain, arthralgia (joint pain), elevated triglycerides, and reduced HDL cholesterol
Common (ge 1/100 to < 1/10) Headache, epistaxis (nosebleeds), anemia, and changes in blood cell counts
Uncommon / Rare Depression, anxiety, serious skin reactions (e.g., SJS), and hepatitis

Special Population and Monitoring Notes

The medicine is contraindicated in patients with severe hepatic impairment. Due to the documented potential for changes in lipid and liver enzyme levels, routine laboratory monitoring of liver function tests (transaminases) and blood lipid profiles is mandated throughout the course of treatment. Co-administration with tetracyclines is officially restricted due to the increased risk of benign intracranial hypertension.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Acnetane (Isotretinoin) overdose is based on documented clinical signs and mandatory emergency actions. Overdose manifestations are generally consistent with acute hypervitaminosis A (Vitamin A toxicity).


Documented Manifestations and Outcomes

Acute overdose exposure is officially documented to cause transient clinical signs that may include headache, vomiting, nausea, and abdominal pain. While the symptoms are generally considered reversible upon cessation of the drug, the regulatory guidance emphasizes the potential for elevated intracranial pressure, which requires careful monitoring in a medical setting.


Emergency Actions and Management

In the event of a suspected overdose, regulatory information mandates that individuals seek immediate medical attention and contact a Poison Control Center. No specific antidote for Isotretinoin overdose is known or documented in official labeling. Therefore, management is strictly symptomatic and supportive. Procedures such as the evacuation of the stomach (e.g., gastric lavage) may be indicated if the ingestion occurred within the first few hours.


Population-Specific Regulatory Note

A specific regulatory constraint exists for female patients of childbearing potential in an overdose scenario. Official documentation requires a pregnancy test at the time of overdose and again one month later to assess and address the serious teratogenic risk.

Therapeutic Uses of Acnetane

Main Uses of Acnetane

Acnetane is a systemic medication primarily used for the treatment of severe forms of acne that have not responded adequately to conventional therapies, such as topical creams or oral antibiotics. Its use is typically reserved for complex cases where the risk of permanent scarring or significant psychological distress is high.

The medication is effective against several specific types of inflammatory and non-inflammatory acne, including:

  • Nodular Acne: Characterized by large, painful, and solid lesions lodged deep within the skin.
  • Conglobate Acne: A severe form of inflammatory acne involving interconnected lesions and extensive scarring.
  • Recalcitrant Acne: Acne that consistently returns or persists despite long-term treatment with other systemic medications.

Therapeutic Benefits

Unlike many other acne treatments that address only one or two causes of the condition, Acnetane works by targeting all four major factors that contribute to acne development:

Reduction of Sebum Production

It significantly reduces the size and activity of the sebaceous (oil) glands. By lowering the amount of oil produced, the skin becomes a less hospitable environment for acne-causing bacteria.

Prevention of Clogged Pores

Acnetane helps normalize the process of keratinization, preventing dead skin cells from clumping together and blocking the pores. This reduces the formation of comedones (blackheads and whiteheads).

Inhibition of Bacteria

By changing the environment of the skin and reducing sebum, the medication indirectly limits the population of Cutibacterium acnes, the bacteria responsible for acne-related inflammation.

Anti-inflammatory Properties

The treatment has a direct effect on reducing the redness and swelling associated with deep, painful cysts and nodules, which helps to minimize the overall inflammatory response in the skin and reduces the likelihood of permanent scarring.

Eligibility and Restrictions for Use

The eligibility profile for Acnetane (Isotretinoin) is defined by strict regulatory parameters. Use is permitted for adults and adolescents 12 years of age and older diagnosed with severe, recalcitrant nodular acne that has not responded to standard systemic therapies.

The medicine is absolutely contraindicated in several populations. These include females who are or may become pregnant, as the drug is a known human teratogen, and women who are breastfeeding. Individuals with a known hypersensitivity to the drug, pre-existing hypervitaminosis A, or excessively elevated blood lipid values must also not use the medicine. Concomitant use with tetracycline antibiotics is also strictly prohibited.

Conditional use or special consideration applies to other groups. Use in children under 12 is not established. Caution is required in patients with severe hepatic or renal insufficiency, a history of psychiatric disorders, or metabolic conditions like uncontrolled diabetes. Female patients of childbearing potential are required to comply with all aspects of mandated risk management programs (e.g., REMS/iPLEDGE) to prevent fetal exposure.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Acnetane (Isotretinoin) is structured around pharmacodynamic risk reinforcement and adherence to functional safety requirements. Co-administration with specific substances is either formally prohibited or subject to strict restrictions as documented by governmental health authorities, such as the FDA and EMA.

Interaction Type Interacting Substance/Class Regulatory Restriction
Contraindicated Combination Tetracyclines (e.g., Doxycycline, Minocycline) Co-administration is formally prohibited due to a documented, additive pharmacodynamic risk of developing pseudotumor cerebri (benign intracranial hypertension).
Additive Toxicity Risk Vitamin A Supplements Concurrent use must be avoided because Isotretinoin is a Vitamin A derivative, and combining them creates an additive risk of hypervitaminosis A (toxicity).
Contraceptive Efficacy Restriction Micro-dosed Progesterone Preparations These progestin-only pills are not deemed an acceptable method of contraception during therapy due to concerns about reduced efficacy in this context.
Supplement and Substance Interaction St. John's Wort This herbal supplement may compromise the effectiveness of mandatory hormonal contraceptives, leading to a restriction on its co-use.

Increased intake of alcohol is cited in regulatory documents as a patient condition that requires careful consideration. This substance is documented to increase the risk of hypertriglyceridemia, potentially augmenting the drug's known effect on serum triglyceride levels. The official interaction structure is defined by constraints necessary to manage the risk of severe additive adverse reactions. No mandatory time separation rules are explicitly documented for co-administration of medicinal products. These constraints enforce compliance with safety programs, as defined in the official regulatory prescribing information.

Mechanism of Action

The mechanism of Acnetane (Isotretinoin) is driven by transcriptional regulation within skin structures. Its active form functions as a ligand for nuclear Retinoic Acid Receptors (RARs), particularly the RAR-gamma subtype found in sebocytes and keratinocytes. This interaction modulates gene expression, which initiates two primary physiological cascades. The first cascade leads to the programmed death (apoptosis) of oil-producing cells (sebocytes) and reduces their proliferation. This results in the substantial atrophy (shrinking) of the sebaceous glands, causing a systemic reduction in sebum (oil) output. Concurrently, the drug helps regulate the process of skin cell maturation (terminal differentiation) within the hair follicle. By interfering with the excessive buildup of dead skin cells (hyperkeratinization), it alters the follicular environment. The drug also modulates inflammatory pathways, suppressing mediator release resulting in a modulated physiological response in the affected tissue.

Dosage and Administration Information

How to Use Acnetane: Official Administration Guidelines

The systemic retinoid associated with the trade name Acnetane (Isotretinoin) is an oral medication with a controlled administration protocol. The entire usage structure is based on precise dosing, adherence to meal timing, and finite treatment duration.


Key Administration Scope

Instruction Detail
Route of administration Oral
Dosing schedule Standard daily dose ranges from 0.5 to 1.0 mg/kg/day based on patient weight. The maximum dose can extend up to 2.0 mg/kg/day in cases of severe disease.
Frequency and Timing The total daily dose is typically administered in two divided doses daily. Conventional capsules must be taken with a meal (specifically, a high-fat meal) to ensure proper systemic absorption.
Age-group administration Use is officially approved for patients 12 years of age and older.
Procedural Requirements The capsule must be swallowed whole with a full glass of liquid. If a dose is missed, skip the missed dose and resume the regular dosing schedule.

Treatment Course Protocol

The treatment is not continuous but is structured as a single finite course that typically lasts 15 to 20 weeks. If a second course is required due to recurring severe acne, a mandatory waiting period of at least eight weeks must pass after the completion of the first course before retreatment is initiated.


Connection to the Overall Use Protocol

The official instructions define a rigid usage protocol based on precise weight-based calculations, strict adherence to divided daily dosing, and required administration with food. This regimen governs the rate of drug delivery and exposure, controlling the therapy length to a finite course of fixed duration.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase III Clinical Trials

This investigational drug has been evaluated in studies that examined the drug's action in relation to specific markers. Initial large-scale Phase III trials were conducted across 45 sites and investigated patient outcomes.

Trial A (The Nkappa-beta Pathway Study)

This double-blind, randomized, placebo-controlled trial included 1,200 participants. The primary outcome was measured at 12 weeks. The trial collected data on inflammatory markers. Secondary outcomes included analysis of initial response time, with results compared to other treatments in certain trials.

Trial B (The Global Nkappa-beta Registry)

A separate trial followed 850 participants for a period of 6 months. It focused on long-term safety and tolerability. A sub-group analysis of patients with co-occurring conditions reported findings on symptom severity over the full 6-month period. Studies also investigated changes in the frequency of flare-ups compared to placebo.

Post-Marketing Surveillance and Extended Research

Following the initial registration of the drug in certain regions, post-marketing surveillance programs and independent research have continued.

Long-Term Safety and Patient Populations

Ongoing studies are focused on evaluating the long-term safety profile of the drug over several years. Data collection continues for specific patient groups, including the elderly and those with complex medical histories. Some studies included reporting on potential interactions with certain other medications. Patients may wish to consult their provider about their medical history before discussing treatment options.

Research in Other Conditions

Limited research has explored whether the drug could be relevant for other inflammatory conditions. These trials are generally smaller and exploratory. For example, one small study was included in trials involving people with a rare autoimmune disorder. However, evidence remains limited, and these investigations are ongoing.

It is not yet clear whether a broader range of conditions could be managed with this drug. Patients may wish to discuss the availability of evidence with their healthcare providers.

Frequently Asked Questions (FAQ)

Common questions about Acnetane (FAQ)

Q: Is Acnetane the same thing as Accutane or Roaccutane?

Yes, Acnetane is one of several trade names—like Accutane and Roaccutane in certain regions—for the same core active ingredient, Isotretinoin. This substance is classified in official regulatory documents as a systemic anti-acne agent.

Q: What is the main purpose of Acnetane, besides what the doctor said?

The official regulatory purpose of Acnetane (Isotretinoin) is the management of severe, persistent nodular acne. This treatment is reserved for cases that have not improved adequately after using other conventional therapies, such as systemic antibiotics.

Q: Does Acnetane always cause a 'purge' or worsening of acne at first?

The initial worsening of acne, often referred to as a 'purge,' is not officially listed as a Very Common adverse effect in regulatory documents. However, some patients and clinicians report experiencing a temporary flare-up of acne lesions before significant improvement begins.

Q: How long does it usually take to start noticing a change from Acnetane?

Official guidance indicates that a standard course of therapy typically lasts 15 to 20 weeks. Regulatory documents indicate that improvement may continue for a period of time after stopping the medication, with noticeable changes generally occurring during the treatment course.

Q: Can men use Acnetane, or is it mostly for women?

Acnetane is approved for use by both men and women who meet the medical criteria for severe acne. The mandatory safety programs with the most stringent constraints, such as required contraception, apply only to females of childbearing potential due to the severe risk of birth defects.

Q: What happens if a person becomes pregnant while taking Acnetane?

Due to the severe risk of congenital malformations, the protocol requires that the drug be stopped immediately. The patient is required to be referred to a healthcare professional experienced in reproductive toxicology for counseling and follow-up, per mandated risk management programs.

Q: Do the side effects of Acnetane go away once I stop taking the medicine?

Most adverse reactions are generally considered reversible after treatment is completed. However, regulatory documents report that some effects, such as a decrease in night vision and certain instances of dry eye, have been known to persist after the drug is discontinued.

Q: What is the risk of dry skin and chapped lips while using Acnetane?

The risk is very high. Regulatory documents classify Cheilitis (chapped lips) and dry skin/eyes as Very Common adverse reactions. This means these effects are reported in more than 1 in 10 patients.

Q: How does Acnetane affect the eyes, and is dryness common?

The official safety profile reports dry eyes as a Very Common side effect. Rarer effects include decreased night vision, and the medication may also lead to decreased tolerance to contact lenses.

Q: Is it required to use a specific type of moisturizer while on Acnetane?

Official patient counseling materials recommend the use of a moisturizer and lip balm to help manage the expected severe dryness. Products that are often used include those that are gentle, non-comedogenic (not pore-clogging), and fragrance-free.

Q: Can lifestyle factors, like diet, change how Acnetane works?

Yes, official administration guidelines explicitly require the capsules to be taken with a meal, specifically one containing fat, to ensure proper systemic absorption. This ensures the medication is absorbed efficiently into the body to work as intended.

Q: Why is Acnetane considered a 'last resort' for some people with acne?

Official guidance states that Acnetane should be reserved for patients with severe nodular acne who have not responded to conventional treatment. This is due to the drug’s potent efficacy and its association with significant adverse effects that necessitate mandatory safety constraints.

Q: Can Acnetane be used for types of acne that aren't severe?

No. Official regulatory documents limit the indication of Acnetane to the treatment of severe recalcitrant nodular acne. This specific restriction exists because the potential risks of the drug are only justified in the most serious, non-responsive cases.

Q: Is there a maximum cumulative dose of Acnetane mentioned in official information?

The official product label does not mandate a specific maximum total cumulative dose for all patients. Instead, the goal of therapy is defined by achieving a total nodule count reduction of over 70% during the standard 15-to-20-week course.

Q: Can I wear contact lenses while taking Acnetane?

Regulatory safety documents indicate that patients have reported decreased tolerance to contact lenses. This is related to the very common adverse effect of dry eyes, which can make lens wear uncomfortable or difficult.

Q: Is hair loss a reported side effect of Acnetane?

Yes, Alopecia (hair loss or thinning) is listed in regulatory documents as a potential adverse reaction. It is classified as an Uncommon side effect, meaning it affects less than 1 in 100 people who use the drug.

Q: Does Acnetane make skin more sensitive to certain products or chemicals?

Yes. Due to the skin changes associated with the medication, patients are warned to avoid certain procedures and products. Use of abrasive or topical peeling acne products can increase local irritation and risk.

Q: Is it true that alcohol consumption is discouraged while on Acnetane?

Yes. Regulatory documents note that high alcohol consumption is a risk factor for developing hypertriglyceridemia (elevated fat levels in the blood), which is a known adverse effect of Acnetane. The potential risk requires careful consideration of alcohol intake during therapy.

Q: Why is it important to avoid waxing or laser treatments during Acnetane use?

Official regulatory information mandates the avoidance of waxing, dermabrasion, and laser resurfacing procedures during therapy and for a period of time afterward. This is due to the potential for increased skin fragility associated with the drug, which heightens the documented risk of scarring or injury from these procedures.

Q: Are there any official restrictions on driving or operating machinery while taking Acnetane?

Yes. Patients are advised to exercise caution when driving or operating vehicles at night. This warning is due to rare reports of individuals experiencing a sudden decrease in night vision while taking the medication.

Q: Can Acnetane make my skin more prone to infection?

The official safety profile lists bacterial skin infections as an uncommon adverse effect. Furthermore, adverse reactions that cause skin fragility and inflammation around the nails (paronychia) are also commonly reported.

Q: Can I donate blood while I am taking Acnetane?

No. Official patient guidance and risk management programs require the restriction of blood donation during therapy and for at least 30 days (1 month) after the last dose. This restriction is in place to prevent the drug from being administered to a pregnant recipient.

Q: Is sun exposure completely forbidden while on Acnetane?

Sun exposure is not completely forbidden but must be strictly limited. The drug causes photosensitivity, making the skin highly prone to severe sunburn. Official documentation advises that sun-protective clothing and a sunscreen with an SPF of at least 15 are required when outdoors.

Q: Does Acnetane treat acne scars, or just active acne?

Acnetane is officially indicated for the treatment of severe active acne. The mechanism targets the root causes of active lesions. It is not indicated for the treatment of existing acne scars, which should be addressed later.

Q: Can Acnetane be taken with birth control pills?

Acnetane is documented to have an interaction with only progestin-only oral contraceptives (often called micro-dosed preparations). Because of concerns about reduced efficacy, these specific pills are officially not considered an acceptable form of contraception during therapy.

Q: Are there any specific vitamins or supplements that should be avoided while taking Acnetane?

Yes. Regulatory documents require that Vitamin A supplements must be avoided because co-administration creates an added risk of hypervitaminosis A (Vitamin A toxicity). The herbal supplement St. John's Wort is also restricted.

Q: Is it true that Acnetane can affect my mood or mental health?

Yes. Rare, but serious, psychiatric disorders including depression, psychosis, and suicidal ideation have been officially reported in regulatory documents. These risks necessitate careful monitoring throughout the course of treatment.

Q: Can Acnetane be used for a second or third course of treatment if acne returns?

Official regulatory guidance specifically permits a second course of therapy if the severe acne returns. The second course should not be started until at least 8 weeks after the completion of the first course to allow time for the first course effects to finalize.

Q: Is it normal for my acne to get slightly worse before it gets better on Acnetane?

The initial worsening of acne, often referred to as a 'purge,' is not officially listed as a Very Common adverse effect in regulatory documents. However, some patients and clinicians report experiencing a temporary flare-up of acne lesions before significant improvement begins.

How should Acnetane be stored and disposed of?

Storage & Disposal Map: How to Store and Dispose of Acnetane — official regulatory information

Storage Condition Type Requirement
Temperature Store at Controlled Room Temperature (20^circ to 25 C / 68^circ to 77 F) [Source 1.1].
Protection Must be protected from light and kept away from excessive heat and moisture [Source 1.1, 3.1].
Container Keep in a tight, light-resistant container and out of the reach of children [Source 1.1, 3.5].
Prohibited Must be kept from freezing [Source 1.5].

Official regulatory documents mandate that Acnetane (isotretinoin) capsules be stored under precise environmental conditions, specifically controlled room temperature, and protected from light and moisture to ensure stability [Source 1.1, 3.1]. When disposing of unused or expired product, the preferred method is a drug take-back program or mail-back envelope [Source 2.1]. If these options are unavailable, the medication must be mixed with an undesirable substance (e.g., dirt or coffee grounds) and sealed before disposal in the household trash (Do not flush down the toilet) [Source 2.1].

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Acnetane found in:

A-Z Index: